Company
(Location)

Product

Description

Indication

Status

Date


Adherex Technologies Inc. (Research Triangle Park, N.C.)

Eniluracil

Mechanism-based inactivator of DPD

Metastatic breast cancer

Phase II data of the drug in combination with 5-FU and leucovorin in patients who had rapid disease progression on capecitabine treatment showed that 89% had clinical benefit, 33% had tumor responses and patients on EFL had ongoing median progression-free survival of 117 days vs. 42 days for capecitabine

12/11/12

Celldex Therapeutics Inc. (Needham, Mass.)

CDX-011

Glembatamumab vedotin; an antibody-drug conjugate (ADC) that targets and binds to GPNMB

Metastatic breast cancer

Phase IIb data showed that treatment of patients with both triple-negative breast cancer and high GPNMB expression showed high overall response rates for the CDX-011 arm (CDX-011 ORR of 33% vs. 0% in the IC arm) and an overall survival and progression-free survival benefit (PFS) for CDX-011 that reached statistical significance (CDX-011 median survival of 10 months vs. IC of 5.5 months); in patients with high GPNMB expression, a high response rate was observed in the CDX-011 arm (CDX-011 ORR of 32% vs. IC of 13%) and a trend of improvement in overall survival and PFS was demonstrated for the CDX-011 arm

12/11/12

Genentech Inc. (South San Francisco)

Perjeta

Pertuzumab

HER2-positive metastatic breast cancer

Phase III data showed that the combination of Perjeta, Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives of people with previously untreated disease, compared to Herceptin, chemotherapy and placebo

12/11/12

Merrimack Pharma-ceuticals Inc. (Cambridge, Mass.)

MM-302

A nanotherapeutic encapsulation of anthracycline chemotherapy doxorubicin with anti-HER2 antibody fragments attached to its surface

Breast cancer

Phase I data showed that it was safe and tolerable

12/11/12

Puma Biotechnology Inc. (Los Angeles)

PB272

Neratinib

HER2-positive metastatic breast cancer

Phase II data showed that PB272 in combination with temsirolimus had acceptable tolerability in patients with disease progression on Herceptin; efficacy results showed that for the 27 evaluable patients, 12 experienced a partial response and one patient experienced prolonged stable disease for greater than six months, for a clinical benefit rate of 48%

12/11/12


Notes:

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue.

The date indicated refers to the BioWorld Today issue in which the news item can be found.